Genetic Variant Determines Individual GLP‑1 Drug Response
As a medical school professor, I get asked why GLP-1 drugs work miracles for some and barely budge for others. A new Nature paper from 23andMe gives part of the answer: your genes. Researchers ran a genome-wide association study in 27,885 GLP-1 users and found a missense variant in GLP1R -- the receptor semaglutide and... https://www.youtube.com/@RobertLufkinMD https://www.nature.com/articles/s41586-026-10330-z GLP1 #PrecisionMedicine #MetabolicHealth #Pharmacogenomics #HealthLongevitySecrets
RAGE Gene Therapy Cuts Inflammation, Not Lifespan
It's a gene therapy that targets the RAGE pathway (Receptor for Advanced Glycation End-Products) that mediates inflammation and oxidative stress signaling. So far, the mice data doesn't show significant longevity benefits and mostly reduced inflammation and vascular stiffness and kidney damage. On...
Agents Without Moats Will Falter in Fierce Market
Pointed ironies in the SERD wars, plus ADC hype, and what really works in breast cancer... How agents with no moat, no differentiation, and no clear advantage will struggle in a tough competitive market: https://t.co/2Efcy5ItNM https://t.co/FBDM2eDJd4
CYTK Phase 3 Surges After Long Road to Success
$CYTK Phase 3 hits + Been a long ride in that one, but sweet win https://t.co/daXv0EdCSa
Myqorzo ACACIA Study Achieves Dual Primary Endpoint Success
$CYTK Here we go! Myqorzo ACACIA study results in nHCM --> BOTH co-primary endpoints hit with statistical significance. There may be debate about magnitude of improvements for Myqorzo via KCCQ-CSS and peak V02. But, if you were dreaming for a...
Patents Hide Life‑Saving Drug Clues Await Discovery
What if the next life-saving drug is buried in a patent diagram? In early drug discovery, progress can hinge on a single decision. The evidence exists, but some of the most valuable insights stay invisible to conventional search, especially inside...
Full Asset Acquisitions Avoid Margin Drag of Royalties
Seedy is not long enough $ABVX, however I’m old enough to remember when $ABBV spent $21B to buy half of ibrutinib.
New Trial Compares Dara‑Bor‑Dex vs Cy‑Bor‑Dex in MM with LCCN
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/Jrh4teOxUK
Daratumumab Boosts Revlimid Efficacy in Smoldering Myeloma
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/oQzEYsPoU4
Phase 3 Trial
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/zWMK1RfCFW
FDA Likely to Fast‑Track KRAS Drug for PR Boost
To try to offset this, I predict the FDA will approve the $RVMD KRAS drug in record time. Not just much quicker than usual. FDA needs a public relations win, and this will be their vehicle.
Gene Therapy Targets Childhood Blindness by Fixing Retinal Gene
Jean Bennett and Albert Maguire developed a gene therapy approach to correct a gene in the retina to treat childhood blindness. https://t.co/WJ99qvcUT1
Leroy Hood Unveils Dark Proteome Frontier at SynBioBeta 2026
“I am interested in deciphering human complexity in terms of wellness and disease. I guess you would describe me as a multi-disciplinary human biologist.” That is Dr. Lee Hood @ISBLeeHood in one quote. We're excited and honored to have Dr. Leroy Hood...
Kickoff Reception Launches SynBioBeta2026 Networking Opportunities
At 5 PM today in San Jose, #SynBioBeta2026 officially begins. The New Attendee Reception is the first event of the conference, and it's the perfect on-ramp: grab your lanyard, walk the venue, and start meeting the people you'll be running into...
New Toolkit Maps Human Ageing Hallmarks for Translation
🔬 Excited to share our new preprint on a translational toolkit for ageing research. We present a multi-modal approach to profile key hallmarks of human ageing, from immune function to mitochondrial activity and mTOR/autophagy. Our aim is to improve standardisation, reproducibility, biomarker...
One Hepatic Failure Case Sparks LLY vs Novo Debate
$LLY $NVO So one case of hepatic failure reported with $LLY Foundayo. To put this in perspective, with the injectables in this class, the reported hepatic incidents have been well under 1 in 100,000. Other oral GLP-1 agonists have also...
Deviation Capital Launches $300M Fund, Seeks Bio‑tech Founders at SynBioBeta
Deviation Capital just launched with a $300M fund target, and founding partner Dusan Perovic will be at #SynBioBeta2026 this week in San Jose looking for the next generation of founders to back. Deviation spun out of @TwoSigmaVC with a clear thesis:...
Celcuity Bolsters ASCO‑highlighted Breast Cancer Drug Case
Celcuity strengthens case for ASCO-spotlighted breast cancer drug https://t.co/HdekunGXsu by @Lilah_Alvarado $CELC + 18% $NVS $AZN $RHHBY
Annual Grail Liquid Biopsy: Early Cancer Detection for the Wealthy
Everybody with a net worth over $5 million should do a Grail Liquid Biopsy every year. My wife, me and my parents all do it annually. $1k to do it. Every 3 years for $1-5 million net worth. Can give you super early detection...
German Lab Prints Tumors to Study Neutrophil Interactions
One of the cooler things I saw during my visit to Germany last week was this tumor printer. The company is using it to test how neutrophils affect the tumor microenvironment. https://t.co/jXzxDpj6nZ
Funding Cuts and Visa Limits Spark US Brain Drain
#NIH funding cuts & visa crackdowns are driving away talented foreign researchers who normally would have flocked to the US, a @statnews.com survey shows. "It is going to cause a long-term brain drain," one US based researcher told @DrewQJoseph. ...
BEAM Wins TIME 100, Delivers First Gene Base Editing Cure
Congrats to $BEAM on being named as one of @TIME’s 100 most influential & innovative companies that are shaping the world & our future. @beamtx’s leading Gene Editing platform - Base editing, has achieved a significant milestone when KJ Muldoon...
Hantaviruses Counteract Cell Interferon (IFN) Defense
Cells produce interferon when they are infected by viruses. It regulates antiviral responses. Cells produce interferon when infected with hantaviruses. Depending on the hantavirus, it may produce antagonists to counter the defense. And the convention is IFN, not INF. IYKYK
Reflecting on Craig Venter’s Pioneering Genome Era
I enjoyed this remembrance of Craig Venter and the early days of the genome project by @StevenSalzberg1. https://t.co/ggzbrvWlAk
Pharma Embraces AI, Yet Breakthrough Drugs Remain Elusive
JUST IN: The pharmaceutical industry is adopting AI, but new drug discovery through it remains elusive.
Mitochondrial Dysfunction Drives Frailty; Biomarkers Needed for Precision Therapy
The mitochondrial side of frailty "Mitochondrial dysfunction lies at the intersection of musculoskeletal, metabolic, and immune changes underpinning frailty. While integrative biomarker panels have defined metabolic signatures, early diagnosis and personalized therapies remain unmet needs. Longitudinal studies are required to establish...
Low‑dose Endoxifen Cuts Breast Density, Fewer Side Effects
Low-dose endoxifen reduces breast density by up to 26%, matching the effect of tamoxifen but with fewer side effects, suggesting potential for improved preventive strategies in breast cancer. breastcancer
Glucagon Signaling Required for Caloric Restriction Benefits
Glucagon receptor signaling is indispensable for the healthspan effects of caloric restriction in aging male mice https://t.co/xZYiHWkw5s @GeroScienceAGE https://t.co/WcZgdHgsG2
Cell and Gene Therapy Funding Drops, M&A Persists
Investors should be aware of sub-sectors that fall in and out of favor amongst venture capital investors Cell and gene therapies have seen a marked decline in funding since last year. So have nucleic acid therapies, to a lesser extent However, these...
Nature Study Turns Into Immediate
I wrote about this 6 weeks ago at Ground Truths when the 2 @Nature papers by @HugoAerts and colleagues came out. Today it's a "Health Alert"! https://t.co/CgxBU7IAk1 https://t.co/24PijmLhzR
Gene Signature Swiftly Distinguishes Ebola From Other Illnesses
A newly identified gene pattern enables rapid and accurate distinction of Ebola infection from other diseases, offering potential for improved diagnostic tests in outbreak scenarios. genomics
Extensive Edge‑Case Testing Ensures Plasmid Editor Robustness
Make a heap of edge case detection tests for my plasmid editor, even did emoji-as-input catches, lol. I take robustness and data integrity very seriously so I'm making sure all sorts of edge cases are handled gracefully. I even added...
Longevity Genes Trade Growth for Extended Lifespan
if there were no aging, you would not have matured as a man in fact, the most powerful monogenic life-extending mutations in mice impair growth and maturation
Molecular Diagnostics Boom: More Data, Consumer Market Ahead
Awesome, absolutely love this direction of molecular diagnostics/biomarker maximalism. We shouldn’t be afraid of more data. Especially excited to see it longitudinally for people. No reason this can’t be a big consumer market, paid out of pocket...
GLP Success Sparked Unstoppable Peptide Boom
The (hard for some to accept) reality is that the popularity of GLPs, which of course have lots of RCTs to support them, are actually what opened the doors for the immense interest in all the other peptides. People are...
Wearables Transform Clinical Trials with Continuous Real‑World Data
Delighted to share details on an exciting forum that we are hosting here at the Querrey Simpson Institute for Bioelectronics at @NorthwesternU — Advanced Wearable Sensors and the Future of Clinical Trials — on June 24, 2026, at the...
Electronics‑Free Smart Lens Monitors Glaucoma and Releases Medication
Researchers have developed a prototype electronics-free smart contact lens that can track glaucoma in real time and deliver drugs in response. https://spectrum.ieee.org/smart-contact-lens-glaucoma-microfluidics
Missing Enhancer ID Header in 20GB Matrix
You just downloaded a 20GB enhancer x sample matrix. One problem: the first column header is missing. 1/ You stare at a giant matrix. Rows = enhancers. Columns = samples. But there’s no header for the enhancer ID column. https://t.co/rC6ciWOg9Q
Blood Test May Forecast Alzheimer’s Years Before Symptoms
A new study by researchers at Harvard-affiliated Mass General Brigham has found that a blood test has the potential to predict progression of Alzheimer’s disease ***years before*** symptoms or brain scan changes. https://t.co/WtghaB12r2
Vaccines Must Evolve for Climate, Megacities, Anti‑Science Era
May 14 I’m at @ucsc Univ California Santa Cruz delivering the annual Sinsheimer Distinguished Lecture in Biology on Global Vaccines in a time of Climate Change, Megacities, and Anti-science https://t.co/R55Ya6D6ys https://t.co/wc3KmeEFeO
T‑cell Engagers Face Uncertain Future Amid Mixed Readouts
T cell engagers for I&I will have a lot of clinical readouts this year. This update (report from MS) from $AMGN on blinatumomab last week doesn't bode well for the class and it's unclear if next gen formats will...
Epigenetic Reprogramming Enters Human Trials for Vision
Aging biotech has made TIME's "New Frontiers" list. @lifebiosciences is using Yamanaka factors, and the FDA just cleared their first-in-human trial for optic neuropathies. Partial epigenetic reprogramming is no longer theoretical. It's in human trials. https://t.co/ZtVT5PxbHZ https://t.co/OhqLtNfqGT
Low Leukocyte mtDNA and High Inflammation Predict Elderly
Association of leukocyte mitochondrial DNA copy number and inflammation with mortality among older adults https://t.co/AeqAZIv3er
Biotech Expands Beyond Disease, Merging Tech and Medicine
Excited to be speaking on Monday at Mass General Brigham MESH Core 2026 about how biotechnology is moving beyond just treating disease ! Will do my best to bridge tech and medical cultures -- should be fun/spicy🌶️ wish me luck...
Blood Factors Drive Aging or Rejuvenation; Therapies Emerging
Aging is increasingly understood as a system-wide process shaped by factors in the blood, which can actively drive either decline or rejuvenation rather than just reflect it. Emerging therapies that modify the circulatory environment show promise in reversing aspects of...
NMN Curbs Antibody Attacks, Eases Bleeding Disorder
NEW CLINICAL TRIAL RESULT: NMN suppresses harmful antibody-driven immune attacks to alleviate a common bleeding disorder. Authors suggest it may help other autoimmune diseases like lupus and rheumatoid arthritis 🙏🧵 https://t.co/eMvefTFxZo
Longevity Pill May Redefine Human‑dog Bonds
YOUR NEXT DOG A new pill could soon extend dogs’ lives. How will that change our relationship with our pets? By @andersen 🔗https://t.co/u2cuBfKGuU https://t.co/Iaw4uoZfZe
AI's Measured Impact on Biopharma R&D Remains Limited
My 2c on this highly relevant @Loftus @WSJ on ai in biopharma R&D, an article that offers generally measured assessment of ai impact so far, and will not come as surprise to regular @timmermanreport readers…-> https://t.co/KPigSAw5RC
Weekly Biotech Roundup: Top Insights Curated by BiopharmIQ
Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ. This post is a comprehensive recap of the past week in BioTech and gathers the best related posts written by some of the smartest & brightest 𝕏 Bio...
Zuckerberg Funds $500M AI to Model Human Cells
Mark Zuckerberg backs $500 million push to build AI models of human cells as part of long-term effort to cure disease. https://t.co/nLBDaUVj9Z